Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health Inc. daily Stock Chart
GHDX [NASD]
Genomic Health Inc.
Index- P/E- EPS (ttm)-0.98 Insider Own0.70% Shs Outstand32.48M Perf Week9.02%
Market Cap855.85M Forward P/E- EPS next Y-0.02 Insider Trans-10.26% Shs Float31.49M Perf Month-2.52%
Income-31.30M PEG- EPS next Q-0.17 Inst Own93.60% Short Float8.07% Perf Quarter-2.34%
Sales277.00M P/S3.09 EPS this Y-85.70% Inst Trans0.91% Short Ratio12.48 Perf Half Y-15.22%
Book/sh4.65 P/B5.67 EPS next Y96.10% ROA-16.50% Target Price31.18 Perf Year-11.52%
Cash/sh3.69 P/C7.15 EPS next 5Y- ROE-21.00% 52W Range23.00 - 37.74 Perf YTD-17.58%
Dividend- P/FCF- EPS past 5Y-18.80% ROI-16.50% 52W High-30.18% Beta0.40
Dividend %- Quick Ratio4.10 Sales past 5Y13.00% Gross Margin81.80% 52W Low14.57% ATR1.51
Employees752 Current Ratio4.10 Sales Q/Q0.10% Oper. Margin-13.50% RSI (14)51.36 Volatility5.05% 6.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-93.30% Profit Margin-11.30% Rel Volume1.59 Prev Close27.52
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume203.58K Price26.35
Recom2.50 SMA203.17% SMA50-0.74% SMA200-10.85% Volume322,600 Change-4.25%
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-05-15Reiterated Canaccord Genuity Hold $28 → $26
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
Oct-11-11Reiterated RBC Capital Mkts Sector Perform $27 → $21
Oct-05-11Initiated Oppenheimer Perform $20
Feb-09-11Downgrade Ladenburg Thalmann Buy → Neutral
Nov-16-10Initiated Canaccord Genuity Hold $19
Apr-21-10Initiated RBC Capital Mkts Sector Perform
Apr-14-10Initiated William Blair Mkt Perform
Jan-22-10Upgrade Piper Jaffray Neutral → Overweight
Jan-21-10Initiated Jefferies & Co Hold $18
Jan-08-10Initiated ThinkEquity Buy
Jun-11-09Upgrade Thomas Weisel Market Weight → Overweight $23
Oct-08-08Initiated Oppenheimer Perform
Aug-28-15 06:51AM  Genomic Health upgraded by Raymond James
Aug-25-15 11:29AM  Genomic Health, Inc. Q2 Earnings, 2015
Aug-20-15 08:00AM  Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada PR Newswire -6.41%
08:00AM  Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada CNW Group
Aug-18-15 01:55PM  Genomic Health Prostate Cancer Test Wins Medicare Coverage
01:04PM  GENOMIC HEALTH INC Financials
Aug-17-15 08:00AM  Genomic Health's Oncotype DX® Prostate Cancer Test Receives Medicare Coverage PR Newswire +7.81%
Aug-08-15 08:10PM  10-Q for Genomic Health, Inc. at Company Spotlight
Aug-06-15 05:47PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
10:50AM  Genomic Health Q2 Loss Wider than Expected; Tests Ramp Up - Analyst Blog
Aug-04-15 11:30PM  Edited Transcript of GHDX earnings conference call or presentation 4-Aug-15 8:30pm GMT
09:00PM  Still Waiting for Profitability at Genomic Health at Motley Fool
05:30PM  Genomic Health reports 2Q loss
04:30PM  Genomic Health Inc Earnings Call scheduled for 4:30 pm ET today
04:23PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:07PM  Genomic Health Announces Second Quarter 2015 Financial Results and Reports Record International and Prostate Cancer Tests Delivered PR Newswire
07:07AM  Q2 2015 Genomic Health Inc Earnings Release - After Market Close
Jul-31-15 08:57PM  3 Things to Watch as Genomic Health Reports Earnings at Motley Fool
Jul-30-15 08:00AM  Urology Practice Publishes Study Showing Oncotype DX® Increases Use of Active Surveillance in Prostate Cancer Patients by 56 Percent PR Newswire
Jul-29-15 01:30PM  Salesforce.com Aims at Regulated Industries at Investopedia
Jul-28-15 08:00AM  Genomic Health to Announce Second Quarter 2015 Financial Results and Host Conference Call on Tuesday, August 4, 2015 PR Newswire
Jul-14-15 08:00AM  Breast Cancer Research and Treatment Publishes Oncotype DX® DCIS Score Study PR Newswire
Jul-13-15 01:30PM  MTST: Zacks Small Cap Research Initiates Coverage of MTST at Buy
Jun-25-15 02:20PM  Genomic's Oncotype DCIS Score Betters Treatment Guidance - Analyst Blog
Jun-23-15 11:55AM  Healthcare-Focused Fund Camber Capitals Top Picks: Masimo Corporation (MASI), The Medicines Company (MDCO) at Insider Monkey
08:00AM  Journal of Surgical Oncology Publishes Study Showing Oncotype DX® DCIS Score Result Changes Treatment Recommendations in 30 Percent of DCIS Breast Cancer Patients PR Newswire
Jun-17-15 04:03PM  GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
02:30PM  Genomic Health Liquid Biopsy Test Fit for Bladder Cancer - Analyst Blog
Jun-16-15 08:00AM  Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test PR Newswire
Jun-12-15 04:49AM  Edited Transcript of GHDX earnings conference call or presentation 5-May-15 8:30pm GMT
Jun-11-15 08:00AM  Genomic Health to Present Proof-of-Concept Bladder Cancer Liquid Biopsy Data at AACR Precision Medicine Meeting PR Newswire
Jun-01-15 08:00AM  Oncotype DX® Presentations at ASCO in Breast and Prostate Cancer Reinforce Genomic Health's Leadership in Optimizing Cancer Treatment PR Newswire
May-28-15 11:19AM  Two Picks in Small-Cap Pharma With Catalysts at Barrons.com
May-27-15 10:50AM  Genomic's Prostate Cancer Test Recommended by Palmetto - Analyst Blog
08:00AM  Multiple Oncotype DX® Presentations at the American Society of Clinical Oncology Annual Meeting Highlight Genomic Health's Leadership in Personalizing Breast, Prostate Cancer Care PR Newswire
07:57AM  Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference PR Newswire
May-21-15 08:00AM  Genomic Health Announces Favorable Draft Local Coverage Determination from Palmetto GBA® on Medicare Coverage for the Oncotype DX® Prostate Cancer Test PR Newswire
May-20-15 08:00AM  UCSF-led Study Shows Oncotype DX® and MRI May Provide Independent Information in Favorable Risk Prostate Cancer PR Newswire
May-19-15 03:40PM  Genomic Health's Loss Lingers, Profits Expected in 4Q15 - Analyst Blog
May-18-15 08:00AM  Genomic Health Advances Liquid Biopsy Pipeline, Shows Ability to Accurately Monitor Urine for Presence of Bladder Cancer PR Newswire
May-15-15 08:30AM  Oncotype DX® Prostate Cancer Test Improves Risk Assessment for One in Four Men and Reduces Overall Healthcare Costs PR Newswire
May-11-15 08:00AM  St. Gallen International Breast Cancer Guidelines for the Third Time Distinguish Oncotype DX® as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit PR Newswire
May-09-15 08:09PM  10-Q for Genomic Health, Inc. at Company Spotlight
May-07-15 04:49PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
08:00AM  Genomic Health to Present Multiple Oncotype DX® Studies and Positive Liquid Biopsy Results at American Urological Association Annual Meeting May 15-19 PR Newswire
May-06-15 08:12PM  10-K for Genomic Health, Inc. at Company Spotlight
12:30PM  Genomic Health Q1 Loss Wider than Expected, Revenues Lag - Analyst Blog
09:09AM  Genomic Health to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference at noodls
08:00AM  Genomic Health to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference PR Newswire
May-05-15 06:23PM  Genomic Health Announces First Quarter 2015 Financial Results and Reports Record Oncotype DX® Test Volume at noodls
05:57PM  Genomic Health reports 1Q loss
04:30PM  Genomic Health Inc Earnings Call scheduled for 4:30 pm ET today
04:10PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:01PM  Genomic Health Announces First Quarter 2015 Financial Results and Reports Record Oncotype DX® Test Volume PR Newswire
07:07AM  Q1 2015 Genomic Health Inc Earnings Release - After Market Close
Apr-30-15 08:46AM  Genomic Health Announces Publication of Oncotype DX® Prostate Cancer Test Decision Impact Study in Urology Practice, Supporting Wider Adoption and Reimbursement at noodls -5.61%
08:00AM  Genomic Health Announces Publication of Oncotype DX® Prostate Cancer Test Decision Impact Study in Urology Practice, Supporting Wider Adoption and Reimbursement PR Newswire
Apr-28-15 08:00AM  Genomic Health to Announce First Quarter 2015 Financial Results and Host Conference Call on Tuesday, May 5, 2015 PR Newswire
Apr-07-15 04:03PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-20-15 09:02AM  Multiple Data Presentations Demonstrate Positive Direct Patient Impact of Oncotype DX® Breast Cancer Test Globally at noodls
08:00AM  Multiple Data Presentations Demonstrate Positive Direct Patient Impact of Oncotype DX® Breast Cancer Test Globally PR Newswire
Mar-18-15 12:50PM  Genomic Health Prostrate Cancer Test Grows but Hits Margins - Analyst Blog
Mar-12-15 04:47PM  GENOMIC HEALTH INC Files SEC form 10-K, Annual Report
Feb-20-15 04:14PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-15 10:39PM  Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook at noodls
Feb-12-15 09:05AM  Genetic testing firm Invitae tops IPO targets, raises $102M at American City Business Journals
Feb-11-15 10:06AM  Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Feb-10-15 05:33PM  Genomic Health reports 4Q loss
04:30PM  Genomic Health Inc Earnings Call scheduled for 4:30 pm ET today
04:06PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:02PM  Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook PR Newswire
07:07AM  Q4 2014 Genomic Health Inc Earnings Release - After Market Close CCBN
Feb-05-15 07:00AM  Following NICE's Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX® Breast Cancer Test PR Newswire
04:00AM  Inivata Limited Announces New Board Member Patrick Terry PR Newswire
Feb-03-15 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on Tuesday, February 10, 2015 PR Newswire
Feb-02-15 09:03AM  Should You Buy Genomic Health (GHDX) Ahead of Earnings? - Tale of the Tape Zacks
Jan-30-15 04:07PM  GENOMIC HEALTH INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Sta EDGAR Online
Jan-12-15 01:18AM  Genomic Health Plans Line of Liquid-Biopsy Tests for Cancer at The Wall Street Journal
Jan-09-15 09:49PM  Genetic testing firm Invitae seeks IPO of $86 million (Video) at American City Business Journals
Jan-05-15 08:00AM  Genomic Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-18-14 08:00AM  Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer PR Newswire
Dec-16-14 07:30AM  Genomic Health Test Could Reduce Overtreatment Of Breast Cancer at Forbes
Dec-12-14 08:30AM  Oncotype DX® DCIS Score Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer PR Newswire
Dec-11-14 02:40PM  Genomic Health's Liquid Biopsy Tests Positive in Twin Studies Zacks
Dec-10-14 08:00AM  Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast Cancer Test PR Newswire
Dec-09-14 09:00AM  Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests PR Newswire
Dec-04-14 01:40PM  Genomic Health's Oncotype DX: Cancer Testing Made Easier Zacks
Dec-03-14 09:21AM  Genomic Health (GHDX) Downgraded From Hold to Sell at TheStreet
08:00AM  Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations PR Newswire
Dec-02-14 08:00AM  2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on Friday, December 12 PR Newswire
Nov-26-14 04:00PM  Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-19-14 08:00AM  Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact Study To Be Published in European Urology and Urology Practice, Respectively PR Newswire
Nov-12-14 06:02PM  Nasdaq stocks posting largest percentage decreases AP -9.37%
Nov-11-14 09:10AM  New Cancer Detection Technique Has Enormous Potential for Life Science Stocks at 24/7 Wall St.
Nov-10-14 04:08PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-08-14 07:07PM  10-Q for Genomic Health, Inc. Company Spotlight
Nov-06-14 05:12PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
01:50PM  Genomic Health Q3 Loss Narrower than Expected, Revenues Lag Zacks
Nov-04-14 06:31PM  Genomic Health beats 3Q profit forecasts AP
04:05PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cole G BradleyCOOJul 07Option Exercise9.394,00037,56034,326Jul 09 07:25 PM
Cole G BradleyCOOJul 07Sale27.534,000110,11230,326Jul 09 07:25 PM
Cole G BradleyCOOJun 09Option Exercise9.394,00037,56034,326Jun 11 05:34 PM
Cole G BradleyCOOJun 09Sale26.244,000104,96530,326Jun 11 05:34 PM
Cole G BradleyCOOMay 12Option Exercise9.394,00037,56033,658May 14 04:51 PM
Cole G BradleyCOOMay 12Sale27.544,000110,15729,658May 14 04:51 PM
Popovits Kimberly JPresident and CEOApr 13Option Exercise18.893,00056,67037,939Apr 15 04:57 PM
Popovits Kimberly JPresident and CEOApr 13Sale31.283,00093,84034,939Apr 15 04:57 PM
Cole G BradleyCOOApr 07Option Exercise9.394,00037,56033,658Apr 09 04:16 PM
Cole G BradleyCOOApr 07Sale30.444,000121,74729,658Apr 09 04:16 PM
Popovits Kimberly JPresident and CEOMar 12Option Exercise18.893,00056,67037,939Mar 17 05:50 PM
Popovits Kimberly JPresident and CEOMar 12Sale31.913,00095,71734,939Mar 17 05:50 PM
Cole G BradleyCOOMar 10Option Exercise9.394,00037,56033,658Mar 12 04:05 PM
Cole G BradleyCOOMar 10Sale31.844,000127,37629,658Mar 12 04:05 PM
Popovits Kimberly JPresident and CEOFeb 12Option Exercise18.893,00056,67039,965Feb 17 07:12 PM
Popovits Kimberly JPresident and CEOFeb 12Sale29.863,00089,56636,965Feb 17 07:12 PM
Cole G BradleyCOOFeb 10Option Exercise9.394,00037,56025,645Feb 12 05:30 PM
Cole G BradleyCOOFeb 10Sale31.374,000125,46821,645Feb 12 05:30 PM
LIVINGSTON RANDALL SDirectorFeb 02Option Exercise10.731,00010,7307,149Feb 04 04:58 PM
LIVINGSTON RANDALL SDirectorFeb 02Sale31.931,00031,9316,149Feb 04 04:58 PM
Popovits Kimberly JPresident and CEOJan 12Option Exercise18.893,00056,67039,965Jan 14 04:34 PM
Popovits Kimberly JPresident and CEOJan 12Sale33.463,000100,38636,965Jan 14 04:34 PM
Popovits Kimberly JPresident and CEODec 11Option Exercise18.893,00056,67039,365Dec 15 04:13 PM
Popovits Kimberly JPresident and CEODec 11Sale32.993,00098,96736,965Dec 15 04:13 PM
Cole G BradleyCOODec 08Option Exercise9.394,33640,71525,981Dec 09 04:25 PM
Cole G BradleyCOODec 08Sale32.524,336141,00421,645Dec 09 04:25 PM
Popovits Kimberly JPresident and CEONov 12Option Exercise18.894,30081,22739,165Nov 14 07:07 PM
Popovits Kimberly JPresident and CEONov 12Sale34.824,300149,70936,965Nov 14 07:07 PM
Cole G BradleyCOONov 10Option Exercise9.394,00037,56026,891Nov 12 04:32 PM
Cole G BradleyCOONov 10Sale35.354,000141,38822,891Nov 12 04:32 PM
LIVINGSTON RANDALL SDirectorNov 03Option Exercise10.733,00032,1909,149Nov 05 05:01 PM
LIVINGSTON RANDALL SDirectorNov 03Sale36.243,000108,7196,149Nov 05 05:01 PM
Popovits Kimberly JPresident and CEOOct 13Option Exercise18.893,00056,67039,965Oct 15 04:22 PM
Popovits Kimberly JPresident and CEOOct 13Sale30.783,00092,32636,965Oct 15 04:22 PM
Cole G BradleyCOOOct 08Option Exercise9.394,00037,56026,891Oct 10 04:19 PM
Cole G BradleyCOOOct 08Sale28.774,000115,09822,891Oct 10 04:19 PM
Popovits Kimberly JPresident and CEOSep 11Option Exercise16.953,00050,84739,965Sep 15 04:16 PM
Popovits Kimberly JPresident and CEOSep 11Sale29.823,00089,44636,965Sep 15 04:16 PM